The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are: I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
This is a multicentric prospective observational study including patients with suspected arrhythmia-induced cardiomyopathy (AiC) and undergoing rhythm control strategy. AiC suspicion is defined by the presence of left ventricular ejection fraction \<50% with no other more plausible explanation than a new-onset arrhythmia. Patients who met the inclusion/exclusion criteria will be followed during 1 year after the rhythm control procedure (electric cardioversion or catheter ablation) to asess rhythm control status, imaging remodeling and clinical events. A genetic test will be performed during the study time to asess the existace of genetic variants in cardiomyopathy-related genes. Follow-up visits will be scheduled at 2, 6 and 12 months after inclusion and electrocardiogram and echocardiography will be performed. AiC will be confirmed in case of left ventricular ejection fraction recovery \>10% or absolute value \>54% during the follow up imaging evaluations. Primary analysis will asess the prevalence of pathogenic /likely patogenic variants in patients fullfilling AiC criteria and compared with those who not (without AiC). Secondary analysis will be focused on the incidence of cardiovascular events (heart failure-related and rhythm control-related) during the follow up and its relationship with the genetic background and the AiC status. Imaging test during follow up will be performed and changes in ventricular and atrial parameters will be used to asess cardiac remodeling. Further rhythm control asessment will be performed following routinary clinical practice in each participant center.
Study Type
OBSERVATIONAL
Enrollment
109
Ciudad Real General University Hospital
Ciudad Real, Castille-La Mancha, Spain
RECRUITING12 de Octubre University Hospital
Madrid, Madrid, Spain
RECRUITINGAlbacete University Hospital Complex
Albacete, Spain
NOT_YET_RECRUITINGRamón y Cajal University Hospital
Madrid, Spain
ACTIVE_NOT_RECRUITINGPrevalence of pathogenic or likely pathogenic variants in genetic test
Presence of pathogenic/likely pathogenic genetic variant in genetic test
Time frame: Through study completion, an average of 1 year
Heart Failure Admission
Incidence of new hospitalización or urgent visit due to heart failure requiring intravenous diuretics
Time frame: Through study completion, an average of 1 year
Arrhythmia recurrence
Incidence of any atrial tachyarrhytmia (Atrial fibrillation, atrial flutter or atrial tachycardia) conditioning an atrial rate \>150 beats per minute and with a duration of \>5 minutes.
Time frame: Through study completion, an average of 1 year
New unplanned rhythm control procedure
Incidence of unplanned electrical cardioversion or catheter ablation of an atrial tachyarrhythmia (Atrial fibrillation, atrial flutter or atrial tachycardia)
Time frame: Through study completion, an average of 1 year
Atrial reverse remodelling
Incidence of atrial reverse remodelling (ARR). ARR will be considered with a decrease in \>1 degree of atrial dilatation (0=non dilated; 1= mild; 2=moderate; 3=severe) or a decrease \>15% in the left atrial indexed volume
Time frame: Through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.